Lantheus Holdings (LNTH) is well positioned to outperform the market, as it exhibits above-average growth in financials.
The mean of analysts' price targets for Lantheus Holdings (LNTH) points to a 31.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Lantheus Holdings, Inc. excels in radiopharmaceuticals, with PYLARIFY's dominance in PSMA PET imaging. The market for radiopharmaceuticals is expanding beyond all expectations by both industry experts and the company's management. Lantheus is actively expanding its pipeline by making strategic investments backed by a robust balance sheet.